TP53突变急性髓系白血病患者首次诱导或挽救治疗后接受异基因干细胞移植的生存分析:来自髓系恶性肿瘤与肿瘤性疾病联盟(COMMAND)的研究结果
多中心研究分析370例TP53突变急性髓系白血病(AML)患者中68例(18%)桥接异基因造血干细胞移植(allo-HSCT)者的生存预测因素。移植后中位无事件生存期(EFS)12.4个月(95%CI:6.24-18.55),中位总生存期(OS)24.5个月(95%CI:21.80-27.25)。移植后100天完全缓解和慢性移植物抗宿主病(GVHD)的发生与EFS和OS改善独立相关。
要点
- 370例TP53突变AML中68例(18%)接受allo-HSCT,中位年龄63岁(范围33-75)。
- 移植后中位EFS为12.4个月(95%CI:6.24-18.55),中位OS为24.5个月(95%CI:21.80-27.25)。
- 移植后100天完全缓解及慢性GVHD发生与EFS和OS改善独立相关。
核心结论
- allo-HSCT可能为TP53突变AML患者提供改善长期结局的最佳机会。
研究设计与样本
- 多中心研究,分析370例TP53突变AML患者中68例(18%)桥接allo-HSCT者的生存预测因素。
主要发现
- 患者中位年龄63岁(范围33-75),82%有复杂核型,66%有多打击TP53突变。
- 43%接受清髓性预处理,57%接受减低强度预处理;急性GVHD发生率37%,慢性GVHD发生率44%。
- 自allo-HSCT起中位EFS为12.4个月(95%CI:6.24-18.55),中位OS为24.5个月(95%CI:21.80-27.25)。
- 多因素分析中,移植后100天完全缓解对EFS保持显著(HR:0.24,95%CI:0.10-0.57,p=0.001),对OS保持显著(HR:0.22,95%CI:0.10-0.50,p≤0.001)。
- 慢性GVHD发生对EFS保持显著(HR:0.21,95%CI:0.09-0.46,p≤0.001),对OS保持显著(HR:0.34,95%CI:0.15-0.75,p=0.007)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a multi-center study to analyze factors predicting survival among patients with TP53-mutated (m) AML receiving allogeneic hematopoietic stem cell transplant (allo-HSCT) in the recent era. Out of 370 TP53m AML patients, 68 (18%) patients were bridged to allo-HSCT. The median age of the patients was 63 years (range, 33-75), 82% of patients had complex cytogenetics and 66% of patients had multi-hit TP53m. Forty three percent received myeloablative conditioning and 57% received reduced intensity conditioning. The incidence of acute graft versus host disease (GVHD) was 37% and chronic GVHD was 44%. The median event-free survival (EFS) from the time of allo-HSCT was 12.4 months (95% CI: 6.24-18.55) and median overall survival (OS) was 24.5 months (95% CI: 21.80-27.25). In multivariate analysis utilizing variables that showed significance in univariate analysis, complete remission at day 100 post allo-HSCT retained significance for EFS (HR: 0.24, 95% CI: 0.10-0.57, p = 0.001) and OS (HR: 0.22, 95% CI: 0.10-0.50, p ≤ 0.001). Similarly, occurrence of chronic GVHD retained significance for EFS (HR: 0.21, 95% CI: 0.09-0.46, p ≤ 0.001) and OS (HR: 0.34, 95% CI: 0.15-0.75, p = 0.007). Our report suggests that allo-HSCT offers the best opportunity to improve long-term outcome among patients with TP53m AML.
引用
- Badar T, Atallah E, Shallis R, et al. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023. PMID: 36807649. doi:10.1038/s41375-023-01847-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。